CORTISOL PHYSIOLOGY, CAUSES OF ELEVATION, CLINICAL MANIFESTATIONS, AND MODERN TREATMENT APPROACHES
Keywords:
Keywords: cortisol; HPA axis; hypercortisolism; Cushing syndrome; ACTH; adrenal cortex; glucocorticoids; treatment.Abstract
Cortisol is the principal human glucocorticoid and a key effector of the hypothalamic-pituitary-adrenal (HPA) axis. It maintains cardiovascular tone, glucose availability, immune modulation, and adaptive responses to physical and psychological stress. Persistent cortisol excess, however, produces a multisystem disorder characterized by central adiposity, hypertension, glucose intolerance, muscle weakness, osteoporosis, skin changes, reproductive dysfunction, and increased susceptibility to infection. This thesis summarizes cortisol physiology, major physiological and pathological causes of elevation, the clinical pattern of hypercortisolism, current diagnostic principles, and contemporary treatment options. Particular attention is paid to distinguishing transient stress-related cortisol elevation from endogenous Cushing syndrome and from exogenous glucocorticoid exposure.
References
1. Hall, J. E., & Hall, M. E. (2021). Guyton and Hall Textbook of Medical Physiology (14th ed.). Elsevier.
2. Melmed, S., Auchus, R. J., Goldfine, A. B., Koenig, R. J., & Rosen, C. J. (2020). Williams Textbook of Endocrinology (14th ed.). Elsevier.
3. Nicolaides, N. C., Charmandari, E., Chrousos, G. P., & Kino, T. (2015). Circadian endocrine rhythms: the hypothalamic-pituitary-adrenal axis and its actions. Annals of the New York Academy of Sciences, 1318, 71-80.
4. Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008). The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 93(5), 1526-1540.
5. Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015). Treatment of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 100(8), 2807-2831.
6. Cain, D. W., & Cidlowski, J. A. (2017). Immune regulation by glucocorticoids. Nature Reviews Immunology, 17(4), 233-247.
7. Newell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006). Cushing’s syndrome. The Lancet, 367(9522), 1605-1617.
8. Fleseriu, M., Auchus, R., Bancos, I., et al. (2021). Consensus on diagnosis and management of Cushing’s disease: a guideline update. The Lancet Diabetes & Endocrinology, 9(12), 847-875.
9. Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015). The treatment of Cushing’s disease. Endocrine Reviews, 36(4), 385-486.
10. Spiga, F., et al. (2024). The physiological and pharmacological significance of the circadian timing of the HPA axis: a mathematical modeling approach. Journal of Pharmaceutical Sciences, 113(1), 33-46.